SYMBICORT (budesonide and formoterol fumarate dihydrate) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. First approved in 2006.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
SYMBICORT is a fixed-dose combination inhaler containing budesonide (a corticosteroid) and formoterol (a long-acting beta-2 agonist) used to treat asthma and chronic obstructive pulmonary disease (COPD). It works by reducing airway inflammation through corticosteroid receptor agonism while providing bronchodilation via formoterol. The metered-dose aerosol formulation delivers both agents directly to the lungs for rapid and sustained symptom control.
As LOE approaches, the brand is in defensive mode with focus on patient retention, cost management, and preparing organizational transitions; smaller commercial teams expected.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block
Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
Worked on SYMBICORT at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$2.0B Medicare spend — this is a commercially significant brand
Working on SYMBICORT offers exposure to respiratory therapeutics and managed care dynamics in a mature, high-volume franchise with strong reimbursement history. Roles emphasize commercial execution, healthcare analytics, and digital transformation as the brand navigates LOE, with expanding AI/IT roles reflecting AstraZeneca's modernization strategy.
842 open roles linked to this drug